Tag: Kardigan

Kardigan Presents Positive Phase 2 Data on Ataciguat in Patients with Moderate Calcific Aortic Valve Stenosis at American Heart Association Scientific Sessions 2025

Coronary/Structural Heart by 0 comments

Results presented in oral session demonstrated that treatment with ataciguat reduced aortic valve calcium and improved cardiac function and output compared to placebo Download Press Release PDF SOUTH SAN FRANCISCO, Calif., and PRINCETON, N.J., November 7, 2025 — Kardigan, a heart health company modernizing cardiovascular drug development, announced positive Phase 2 […]

Continue Reading →

Kardigan Announces Presentation of Positive Phase 2a Data for Danicamtiv in Patients with Dilated Cardiomyopathy at HFSA Annual Scientific Meeting 2025

Coronary/Structural Heart by 0 comments

Data simultaneously published in The Journal of the American College of Cardiology (JACC) Results presented in late-breaking oral session showed danicamtiv was well tolerated with significant improvements in ventricular and atrial function in patients with genetic dilated cardiomyopathy (DCM) Data supports the planned investigation of danicamtiv in patients with familial […]

Continue Reading →

Kardigan Advances Late-Stage Portfolio of Personalized Cardiovascular Medicines in Dilated Cardiomyopathy, Acute Severe Hypertension and Calcific Aortic Valve Stenosis

Coronary/Structural Heart by 0 comments

By targeting the underlying drivers of disease with a pipeline of complementary candidates, Kardigan is building a platform that accelerates insights into core cardiovascular pathways to address multiple conditions where no treatments exist SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.–(BUSINESS WIRE)–Kardigan, a heart health company modernizing cardiovascular drug development, today […]

Continue Reading →